Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
PubMed
26645190
DOI
10.1016/s0140-6736(15)01021-1
PII: S0140-6736(15)01021-1
Knihovny.cz E-zdroje
- MeSH
- analýza rozptylu MeSH
- antiflogistika aplikace a dávkování škodlivé účinky MeSH
- cyklosporin aplikace a dávkování škodlivé účinky MeSH
- dermatologické látky aplikace a dávkování škodlivé účinky MeSH
- dermatomyozitida farmakoterapie MeSH
- dítě MeSH
- Kaplanův-Meierův odhad MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- methotrexát aplikace a dávkování škodlivé účinky MeSH
- mladiství MeSH
- prednison aplikace a dávkování škodlivé účinky MeSH
- předškolní dítě MeSH
- rozvrh dávkování léků MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- antiflogistika MeSH
- cyklosporin MeSH
- dermatologické látky MeSH
- methotrexát MeSH
- prednison MeSH
BACKGROUND: Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial, the efficacy and safety of prednisone alone with that of prednisone plus either methotrexate or ciclosporin in children with new-onset juvenile dermatomyositis. METHODS: We did a randomised trial at 54 centres in 22 countries. We enrolled patients aged 18 years or younger with new-onset juvenile dermatomyositis who had received no previous treatment and did not have cutaneous or gastrointestinal ulceration. We randomly allocated 139 patients via a computer-based system to prednisone alone or in combination with either ciclosporin or methotrexate. We did not mask patients or investigators to treatment assignments. Our primary outcomes were the proportion of patients achieving a juvenile dermatomyositis PRINTO 20 level of improvement (20% improvement in three of six core set variables at 6 months), time to clinical remission, and time to treatment failure. We compared the three treatment groups with the Kruskal-Wallis test and Friedman's test, and we analysed survival with Kaplan-Meier curves and the log-rank test. Analysis was by intention to treat. Here, we present results after at least 2 years of treatment (induction and maintenance phases). This trial is registered with ClinicalTrials.gov, number NCT00323960. FINDINGS: Between May 31, 2006, and Nov 12, 2010, 47 patients were randomly assigned prednisone alone, 46 were allocated prednisone plus ciclosporin, and 46 were randomised prednisone plus methotrexate. Median duration of follow-up was 35.5 months. At month 6, 24 (51%) of 47 patients assigned prednisone, 32 (70%) of 46 allocated prednisone plus ciclosporin, and 33 (72%) of 46 administered prednisone plus methotrexate achieved a juvenile dermatomyositis PRINTO 20 improvement (p=0.0228). Median time to clinical remission was 41.9 months in patients assigned prednisone plus methotrexate but was not observable in the other two treatment groups (2.45 fold [95% CI 1.2-5.0] increase with prednisone plus methotrexate; p=0.012). Median time to treatment failure was 16.7 months in patients allocated prednisone, 53.3 months in those assigned prednisone plus ciclosporin, but was not observable in patients randomised to prednisone plus methotrexate (1.95 fold [95% CI 1.20-3.15] increase with prednisone; p=0.009). Median time to prednisone discontinuation was 35.8 months with prednisone alone compared with 29.4-29.7 months in the combination groups (p=0.002). A significantly greater proportion of patients assigned prednisone plus ciclosporin had adverse events, affecting the skin and subcutaneous tissues, gastrointestinal system, and general disorders. Infections and infestations were significantly increased in patients assigned prednisone plus ciclosporin and prednisone plus methotrexate. No patients died during the study. INTERPRETATION: Combined treatment with prednisone and either ciclosporin or methotrexate was more effective than prednisone alone. The safety profile and steroid-sparing effect favoured the combination of prednisone plus methotrexate. FUNDING: Italian Agency of Drug Evaluation, Istituto Giannina Gaslini (Genoa, Italy), Myositis Association (USA).
Azienda Ospedaliero Universitaria Meyer Florence Italy
Centro Medico Nacional La Raza Reumatologia Pediatrica Mexico City Mexico
CHU Clinique Médicale Pédiatrique Nantes France
Clinica Pediatrica 1 Unità di Reumatologia Pediatrica Padua Italy
Department of Pediatric Immunology and Rheumatology Wilhelmina Kinderziekenhuis Utrecht Netherlands
Detska Fakultna Nemocnica 1st Pediatric Department Kosice Slovakia
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Clinica Pediatrica 2 De Marchi Milan Italy
Hopital d'Enfants Dijon France
Hôpital Universitaire Hautepierre Pédiatrie 1 Strasbourg France
Hospital de Clinicas Caracas Caracas Venezuela
Hospital de Pediatria Juan P Garrahan Servicio de Inmunología Reumatología Buenos Aires Argentina
Hospital General de Ninos Pedro de Elizalde Rheumatology Section Buenos Aires Argentina
Hospital Universitário Clementino Fraga Filho UFRJ Clinica Medica Reumatologia Rio de Janeiro Brazil
Istituto Gaetano Pini Divisione di Reumatologia Milan Italy
Istituto Giannina Gaslini Epidemiologia Biostatistica e Comitati Genoa Italy
Istituto Giannina Gaslini Pediatria 2 Reumatologia PRINTO Coordinating Centre Genoa Italy
Medizinische Hochschule Hannover Kinderklinik Hannover Germany
Oslo University Hospital Rikshospitalet Department of Rheumatology Oslo Norway
Ospedale Pediatrico Bambino Gesù Reumatologia Rome Italy
Paediatric Nephrology and Internist Medicine Hôpital des Enfants Toulouse France
Pediatric Rheumatology Unit Karolinska University Hospital Stockholm Sweden
Skejby Sygehus Aarhus University Hospital Department of Pediatrics Aarhus Denmark
Universitair Ziekenhuis Gent Centrum Voor Kinderreumatologie Gent Belgium
Citace poskytuje Crossref.org
Idiopathic inflammatory myopathies
Idiopathic inflammatory myopathies
Consensus-based recommendations for the management of juvenile dermatomyositis
ClinicalTrials.gov
NCT00323960